Product approvals, OTC labeling not covered by risk assessment bills in Congress.
This article was originally published in The Tan Sheet
Executive Summary
PRODUCT APPROVALS WOULD BE EXEMPT FROM COST/BENEFIT ANALYSES OF RISK under a substitute amendment to Title III of the "Job Creation and Wage Enhancement Act" (HR 9) offered by Reps. Michael Oxley (R-Ohio) and Michael Bilirakis (R-Fla.) during a House Commerce Committee markup Feb. 8. Oxley chairs the commerce & trade subcommittee while Bilirakis is chair of the health subcommittee.